TABLE 1.
Baseline characteristics of HCV+ persons with and without SARS‐CoV‐2 infection
| SARS‐CoV‐2 POS | SARS‐CoV‐2 NEG | P‐value | |
|---|---|---|---|
| N = 892 | N = 13,413 | ||
| Median age, y (IQR) | 61 (56, 65) | 60 (55, 64) | <.0001 |
| Race, % | <.0001 | ||
| White | 28.14% | 47.98% | |
| Black | 55.16% | 37.81% | |
| Hispanic | 5.27% | 4.03% | |
| Other/unknown | 11.43% | 10.18% | |
| Sex, % male | 95.96% | 95.74% | .74 |
| Body mass index | |||
| Mean, SD | 28.4 (5.8) | 27.9 (5.8) | .02 |
| >30 | 36.22% | 29.69% | <.0001 |
| Median HCV RNA, log10 (IQR) | 5.8 (1.3, 7.1) | 5.8 (1.2, 7.3) | .35 |
| FIB‐4 score | |||
| Mean FIB‐4 score (SD) | 2.4 (2.6) | 2.5 (3.2) | .84 |
| FIB‐4 > 3.25, % | 15.25% | 17.33% | .11 |
| Comorbidities, % | |||
| Hypertension | 66.37% | 63.25% | .06 |
| Diabetes | 35.09% | 28.41% | <.0001 |
| Coronary artery disease | 0.45% | 0.57% | .63 |
| Stroke | 7.29% | 4.20% | <.0001 |
| Cancer | 10.65% | 10.86% | .84 |
| Chronic obstructive pulmonary disease | 14.80% | 14.53% | .83 |
| Smoking, % | <.0001 | ||
| Current | 46.41% | 59.26% | |
| Former | 27.91% | 21.32% | |
| Never | 21.52% | 15.78% | |
| Unknown | 4.15% | 3.64% | |
| Alcohol use disorder, % | 22.87% | 28.20% | .001 |
| Drug use disorder, % | 28.92% | 35.47% | <.0001 |
| Treated for HCV, % | 70.40% | 71.33% | .55 |
| Attained sustained virologic response, % | 91.73% | 92.02% | .80 |
| Admitted to hospital | 35.87% | 30.49% | .001 |
| Admitted to ICU | 12.33% | 6.93% | <.0001 |
| Died | 6.17% | 1.71% | <.0001 |